Birdwatch Note
2023-11-03 07:05:31 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
ワクチン後遺症との主張は根拠不明。 新型コロナワクチンは高い発症・重症化予防効果を示したが、100%ではない。 https://www.nejm.org/doi/full/10.1056/nejmoa2034577 | NEJM プラセボ群との対照試験の結果、ファイザー社製ワクチンの治験にて接種群約18,000人中一人の重症化例が確認されている。 元より完全な防御をもたらす訳ではない。 https://www.fizz-di.jp/archives/1078840555.html |〜Fizz Drug Information〜 日本での三回目接種数は2023/11/3現在約8662万回で全人口の約7割に当たる。 その中から、この報道のような事例が発生しうる可能性は十分に考えられる。 https://info.vrs.digital.go.jp/dashboard|デジタル庁
Written by 8C120F8B617DBAC9E4696DE6F24E78952C3CAB0AAA8B11A719AE451FCC3B40DD
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1720064754511913223
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1720336386077905107
- noteId - 1720336386077905107
- participantId -
- noteAuthorParticipantId - 8C120F8B617DBAC9E4696DE6F24E78952C3CAB0AAA8B11A719AE451FCC3B40DD Participant Details
- createdAtMillis - 1698995131404
- tweetId - 1720064754511913223
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- ワクチン後遺症との主張は根拠不明。 新型コロナワクチンは高い発症・重症化予防効果を示したが、100%ではない。 https://www.nejm.org/doi/full/10.1056/nejmoa2034577 | NEJM プラセボ群との対照試験の結果、ファイザー社製ワクチンの治験にて接種群約18,000人中一人の重症化例が確認されている。 元より完全な防御をもたらす訳ではない。 https://www.fizz-di.jp/archives/1078840555.html |〜Fizz Drug Information〜 日本での三回目接種数は2023/11/3現在約8662万回で全人口の約7割に当たる。 その中から、この報道のような事例が発生しうる可能性は十分に考えられる。 https://info.vrs.digital.go.jp/dashboard|デジタル庁
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-11-03 07:05:31 UTC (1698995131404) |
1969-12-31 23:59:59 UTC (-1) |
2023-11-04 03:04:16 UTC (1699067056450) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-11-03 18:32:43 -0500 | Rating Details | |
2023-11-03 17:34:51 -0500 | Rating Details | |
2023-11-03 15:47:50 -0500 | Rating Details | |
2023-11-03 15:32:58 -0500 | Rating Details | |
2023-11-03 12:48:47 -0500 | Rating Details | |
2023-11-03 09:35:49 -0500 | Rating Details | |
2023-11-03 09:27:42 -0500 | Rating Details | |
2023-11-03 09:25:15 -0500 | Rating Details | |
2023-11-03 07:27:57 -0500 | Rating Details | |
2023-11-03 06:32:39 -0500 | Rating Details | |
2023-11-03 05:37:35 -0500 | Rating Details | |
2023-11-03 05:20:54 -0500 | Rating Details | |
2023-11-03 04:55:05 -0500 | Rating Details | |
2023-11-03 04:32:54 -0500 | Rating Details | |
2023-11-03 04:21:14 -0500 | Rating Details | |
2023-11-03 04:09:59 -0500 | Rating Details | |
2023-11-03 04:01:59 -0500 | Rating Details | |
2023-11-03 03:46:32 -0500 | Rating Details | |
2023-11-03 03:42:24 -0500 | Rating Details | |
2023-11-03 03:29:35 -0500 | Rating Details | |
2023-11-03 03:27:25 -0500 | Rating Details | |
2023-11-03 03:17:13 -0500 | Rating Details | |
2023-11-03 02:59:23 -0500 | Rating Details | |
2023-11-03 02:44:26 -0500 | Rating Details | |
2023-11-03 02:41:50 -0500 | Rating Details | |
2023-11-03 02:41:33 -0500 | Rating Details | |
2023-11-03 02:41:05 -0500 | Rating Details | |
2023-11-03 02:39:23 -0500 | Rating Details | |
2023-11-03 02:17:44 -0500 | Rating Details | |
2023-11-03 02:15:15 -0500 | Rating Details | |
2023-11-03 02:12:37 -0500 | Rating Details | |
2023-11-03 02:08:38 -0500 | Rating Details | |
2023-11-04 02:53:59 -0500 | Rating Details | |
2023-11-04 00:22:18 -0500 | Rating Details | |
2023-11-04 00:09:56 -0500 | Rating Details | |
2023-11-03 21:10:09 -0500 | Rating Details | |
2023-11-03 19:44:41 -0500 | Rating Details | |
2023-11-03 19:34:12 -0500 | Rating Details | |
2023-11-05 10:28:02 -0600 | Rating Details | |
2023-11-06 06:30:04 -0600 | Rating Details | |
2023-11-06 00:58:16 -0600 | Rating Details | |
2023-11-05 19:59:51 -0600 | Rating Details | |
2023-11-08 18:19:16 -0600 | Rating Details | |
2023-11-08 05:17:15 -0600 | Rating Details | |
2023-11-08 04:54:30 -0600 | Rating Details | |
2023-11-03 03:11:28 -0500 | Rating Details | |
2023-11-19 04:01:47 -0600 | Rating Details | |
2023-12-01 09:24:26 -0600 | Rating Details | |
2024-02-21 18:53:37 -0600 | Rating Details | |
2024-03-03 16:58:58 -0600 | Rating Details | |
2024-03-03 02:23:00 -0600 | Rating Details | |
2024-02-22 05:22:56 -0600 | Rating Details | |
2024-02-22 05:20:37 -0600 | Rating Details | |
2024-03-07 06:59:39 -0600 | Rating Details | |
2024-03-06 15:02:42 -0600 | Rating Details | |
2024-03-06 13:57:58 -0600 | Rating Details | |
2024-03-03 01:53:05 -0600 | Rating Details | |
2024-02-21 23:19:33 -0600 | Rating Details | |
2024-02-21 22:41:51 -0600 | Rating Details | |
2024-03-10 01:19:26 -0600 | Rating Details | |
2024-03-08 01:47:38 -0600 | Rating Details | |
2024-03-06 16:33:18 -0600 | Rating Details | |
2024-09-14 23:53:32 -0500 | Rating Details |